Provided by Tiger Trade Technology Pte. Ltd.

Moderna, Inc.

50.96
-0.3200-0.62%
Post-market: 51.040.0835+0.16%19:59 EDT
Volume:6.28M
Turnover:324.03M
Market Cap:20.13B
PE:-7.02
High:52.89
Open:51.67
Low:50.02
Close:51.28
52wk High:59.55
52wk Low:22.28
Shares:394.94M
Float Shares:363.29M
Volume Ratio:1.45
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.2600
EPS(LYR):-7.2600
ROE:-28.87%
ROA:-14.51%
PB:2.33
PE(LYR):-7.02

Loading ...

Moderna Exec Says Co Is "Hoping for" Approval of the Flu-Covid Combination Vaccine in Europe This Year -Conf Call

THOMSON REUTERS
·
Feb 13

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings. -- Barrons.com

Dow Jones
·
Feb 13

BRIEF-Moderna - Announces Influenza Vaccine Filing Accepted For Regulatory Review In The EU

Reuters
·
Feb 13

Moderna Q4 revenue beats estimates on COVID vaccine sales, influenza vaccine filing accepted

Reuters
·
Feb 13

Earnings Flash (MRNA) Moderna Posts Q4 Loss $2.11 a Share, vs. FactSet Est of $2.51 Loss

MT Newswires Live
·
Feb 13

Moderna beats fourth-quarter revenue estimates

Reuters
·
Feb 13

Moderna Beats Quarterly Revenue Estimates On Resilient Sales Of COVID Shot

Reuters
·
Feb 13

Moderna Q4 net income posts USD -0.80 billion loss, down 30 percent in revenue to USD 0.68 billion

Reuters
·
Feb 13

BRIEF-Moderna Q4 EPS USD -2.11 Vs. IBES Estimate USD -2.64

Reuters
·
Feb 13

Moderna - in 2026 Company Is Targeting up to 10% Growth From 2025 Revenue

THOMSON REUTERS
·
Feb 13

Moderna - Announces Influenza Vaccine Filing Accepted for Regulatory Review in the EU

THOMSON REUTERS
·
Feb 13

Moderna - Announces Norovirus Phase 3 Trial Fully Enrolled With a Data Readout Expected in 2026

THOMSON REUTERS
·
Feb 13

Moderna - Q4 Product Sales $264 Mln in the U.S. and $381 Million in International Markets

THOMSON REUTERS
·
Feb 13

Moderna: Seasonal Vaccines Expected to Deliver up to 10% Revenue Growth in 2026

THOMSON REUTERS
·
Feb 13

Moderna - Expects 2026 Revenue Split to Be Approximately 50% U.S. and Approximately 50% International

THOMSON REUTERS
·
Feb 13

Moderna Outlook FY Capex USD 200-300 Million

THOMSON REUTERS
·
Feb 13

Moderna Q4 EPS USD -2.11 VS. Ibes Estimate USD -2.64

THOMSON REUTERS
·
Feb 13

It's been a software horror show. Here's why it could get even scarier, according to Citi.

Dow Jones
·
Feb 13

U.S. Earnings Preview: Before Market Open Feb. 13

Dow Jones
·
Feb 13

Is Moderna (MRNA) Now Fairly Priced After Its Recent Share Price Rebound?

Simply Wall St.
·
Feb 13